Patents by Inventor Michael Brian Tyers

Michael Brian Tyers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6569883
    Abstract: The invention relates to the use of compounds of the general formula (I) wherein R1 represents a hydrogen atom or a C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-(C1-4)alkyl, C3-6 alkenyl, C3-10 alkynyl, phenyl or phenyl-C1-3 alkyl group; and one of the groups represented by R2, R3 and R4 is a hydrogen atom or a C1-6 alkyl, C3-7cycloalkyl, C2-6 alkenyl or phenyl-C1-3 alkyl group and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C1-6 alkyl group; and physiologically acceptable salts and solvates thereof, for the relief of nausea and vomiting and/or the promotion of gastric emptying and for the manufacture of a medicament for this purpose.
    Type: Grant
    Filed: May 5, 1999
    Date of Patent: May 27, 2003
    Assignee: Glaxo Group Limited
    Inventors: Michael Brian Tyers, Ian Harold Coates, David Cedric Humber, George Blanch Ewan, James Angus Bell
  • Patent number: 6544550
    Abstract: The invention relates to the co-administration in human or veterinary medicine of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one or a physiologically acceptable salt or solvate thereof and dexamethasone or a physiologically acceptable salt or ester thereof. The two active ingredients, which may be administered separately either simultaneously or sequentially, or may be combined in a single pharmaceutical preparation, are useful in the relief and/or prevention of nausea and vomiting.
    Type: Grant
    Filed: November 24, 1993
    Date of Patent: April 8, 2003
    Assignee: Glaxo Group Limited
    Inventors: Michael Brian Tyers, Teresa Elizabeth Challoner
  • Patent number: 6221878
    Abstract: The invention relates to the use of compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT3 receptors for the treatment of depression.
    Type: Grant
    Filed: March 10, 1995
    Date of Patent: April 24, 2001
    Assignee: Glaxo Group Limited
    Inventor: Michael Brian Tyers
  • Patent number: 5922749
    Abstract: The invention relates to the use of compounds of the general formula (I) ##STR1## wherein R.sup.1 represents a hydrogen atom or a C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl-(C.sub.1-4) alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, phenyl or phenyl-C.sub.1-3 alkyl group; and one of the groups represented byR.sup.2, R.sup.3 and R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6 alkenyl or phenyl-C.sub.1-3 alkyl group and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkyl group;and physiologically acceptable salts and solvates thereof, for the relief of nausea and vomiting and/or the promotion of gastric emptying and for the manufacture of a medicament for this purpose. Promotion of gastric emptying may be for the relief of gastro-intestinal disorders associated with gastric stasis or may be of advantage in radiological examination procedures.
    Type: Grant
    Filed: August 16, 1996
    Date of Patent: July 13, 1999
    Assignee: Glaxo Group Limited
    Inventors: Michael Brian Tyers, Ian Harold Coates, David Cedric Humber, George Blanch Ewan, James Angus Bell